Bendamustine in the treatment of non-Hodgkin’s lymphomas

References

• Cancer Facts and Figures 2008Atlanta, GAAmerican Cancer Society2008Available from: http://www.cancer.org/downloads/STT/2008CAFFfinalsecured.pdf Accessed June 23, 2009.
   Google Scholar
• BrockmanBTherapy of the recurrence of malignant lymphomaZ Arztl Fortbild (Jena)1992868438461384247
   PubMedGoogle Scholar
• HartmannMZimmerCHInvestigation of cross-link formation in DNA by alkylating cytostatic IMET 3106, 3393 and 3943Biochem Biophys Acta19722873863894629776
   PubMed Web of Science ®Google Scholar
• StrumbergDHarstrickADollKBendamustine hydrochloride activity against doxorubicine-resistant human breast cancer cell linesAnticancer Drugs199674154218826610
   PubMed Web of Science ®Google Scholar
• LeoniLMBaileyBReifertJBendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agentsClin Cancer Res20081430931718172283
   PubMed Web of Science ®Google Scholar
• WeideRBendamustine HCL for the treatment of relapsed indolent non-Hodgkin’s lymphomaTher Clin Risk Manage20084727732
   PubMedGoogle Scholar
• BremerKHigh rates of long-lasting remissions after 5-day bendamustine chemotherapy cycles in pre-treated low-grade non-Hodgkin’s lymphomasJ Cancer Res Clin Oncol200212860360912458340
   PubMed Web of Science ®Google Scholar
• OwenJSMelhemMD’AndreaDDarwishMPopulation pharmacokinetics of bendamustine and metabolites in patients with indolent non-Hodgkin lymphomaClin Pharmacol Ther200883Suppl 1S54S55(Abstract P11–41).
   Google Scholar
• BalfourJAGoaKLBendamustineDrugs200161563164011368287
   PubMed Web of Science ®Google Scholar
• MatthiasMPreissRSohrRPharmacokinetics of bendamustine in patients with malignant tumors [abstract]Proc Am Soc Clin Oncol1995141476
   Google Scholar
• PreissRSohrRMatthiasMThe pharmacokinetics of bendamustine (Cytostasan) in humansPharmazie1985407827844095129
   PubMed Web of Science ®Google Scholar
• HeiderANiederleNEfficacy and toxicity of bendamustine in patients with relapsed low-grade non-Hodgkin’s lymphomaAnticancer Drugs20011272572911593053
   PubMed Web of Science ®Google Scholar
• TulpuleASchillerGHarvey-BuchananLACladribine in the treatment of advanced relapsed or refractory low and intermediate grade non-Hodgkin’s lymphomaCancer199883237023769840537
   PubMed Web of Science ®Google Scholar
• McLaughlinPRobertsonLEKeatingMJFludarabine phosphate in lymphoma: an important new therapeutic agentCabanillasFRodriguezMAAdvances in Lymphoma ResearchBoston, MAKluwer Academic1997314
   Google Scholar
• DeardenCEMatutesECatovskyDClinical overview of pentostatin (Nipent) use in lymphoid malignanciesSemin Oncol2000272 Suppl 5222610877047
   PubMed Web of Science ®Google Scholar
• CabanillasFHorningSKaminskiMChamplinRManaging indolent lymphomas in relapse: Working our way through a plethora of optionsHematology Am Soc Hematol Educ Program200016617911701541
   PubMedGoogle Scholar
• WeidmannEKimSZRostABendamustine is effective in relapsed or refractory aggressive non-Hodgkin’s lymphomaAnn Oncol2002131285128912181253
   PubMed Web of Science ®Google Scholar
• YounesAPretiHAHagemeisterFPaclitaxel plus topotecan treatment for patients with relapsed or refractory aggressive non-Hodgkin’s lymphomaAnn Oncol20011292392711521796
   PubMed Web of Science ®Google Scholar
• SavageDGRuleSAJTigheMGemcitabine for relapsed or resistant lymphomaAnn Oncol20001159559710907954
   PubMed Web of Science ®Google Scholar
• CoifferBHaiounCKettererNRituximab (anti-Cd20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase II studyBlood19989619271932
   Google Scholar
• WiernikPLossosITuscanoJLenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin’s lymphomaJ Clin Oncol2008264952495718606983
   PubMed Web of Science ®Google Scholar
• CzuczmanMVoseJZinzaniPConfirmation of the efficacy and safety of lenalidomide oral monotherapy in patients with relapsed or refractory diffuse large B-cell lymphoma: Results of an international study (NHL-003)Blood (ASH Annual Meeting Abstracts)2008268
   Google Scholar
• JohnstonPAnsellSColganJPhase II trial of the oral mTOR inhibitor everolimus (RAD001) for patients with relapsed or refractory lymphoma. 2007 ASCO Annual Meeting Proceedings – Post meeting editionJ Clin Oncol20072518S8055
   Google Scholar
• WitzigTGeyerSGhobrialIPhase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphomaJ Clin Oncol2005235347535615983389
   PubMed Web of Science ®Google Scholar
• CoiffierBFeugierPSebbanCLong term results of the GELA study, R-CHOP vs CHOP in elderly patients with diffuse large B-cell lymphomaBlood (ASH Annual Meeting Abstracts)20041041383
   Google Scholar
• FreidbergJWCohenPChenLBendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin’s lymphoma: Results from a phase II multicenter, single-agent studyJ Clin Oncol2008262204210Erratum in: J Clin Oncol 2008;10(26):191118182663
   PubMed Web of Science ®Google Scholar
• KahlBSBartlettNLeonardJBendamustine is safe and effective in patients with rituximab-refractory indolent B-cell NHLProceedings of the 49th Annual Meeting of the American Society of Hematology2007 Dec 4–8Atlanta, GABlood 2007:1351
   Google Scholar
• Solal-CélignyPRoyPColombatPFollicular lymphoma international prognostic indexBlood20041041258126515126323
   PubMed Web of Science ®Google Scholar
• ForstpointnerRDreylingMReppRThe addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low-Grade Lymphoma Study GroupBlood20041043064307115284112
   PubMed Web of Science ®Google Scholar
• van OersMKlasaRMarcusRRituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: Results of a prospective randomized phase 3 intergroup trialBlood20061083295330116873669
   PubMed Web of Science ®Google Scholar
• RummelMJChowKUHoelzerDMitrouPSWeidmannEIn vitro studies with bendamustine: Enhanced activity in combination with rituximabSemin Oncol200629121412170426
   PubMed Web of Science ®Google Scholar
• RummelMJAl-BatranSEKimSZBendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin’s lymphomaJ Clin Oncol2005233383338915908650
   PubMed Web of Science ®Google Scholar
• RummelMJWelslauAMKofahl-KrauseDBendamustine and rituximab (BR) are effective in the treatment of relapsed or refractory indolent and mantle cell lymphomas: Long-term follow-up of a phase II studyChicago, ILProceedings from the 43rd Annual Meeting of the American Society of Clinical Oncology2007 Jun 2–5Blood. 8034.
   Google Scholar
• RummelMJHeineKBodensteinHEfficacy and safety of bendamustine and rituximab in the treatment of indolent and mantle cell lymphomas in older patients. Chicago, IL: Proceedings from the 44th Annual Meeting of the American Society of Clinical OncologyJ Clin Oncol2008Suppl8572
   Web of Science ®Google Scholar
• LaknerVEschenburgHAldaoudABendamustine and rituximab in the treatment of relapsed CD20+ non-Hodgkin lymphoma – a phase II study of the East German Study Group of Haematology and OncologyLugano, SwitzerlandProceedings from the 10th International Conference on Malignant Lymphoma2008 June 4–7
   Google Scholar
• MohrenMHeroldMScheinpflugKBendamustine/Mabthera in patients with relapsed or refractory aggressive CD20+ B-cell lymphomaLugano, SwitzerlandProceedings from the 10th International Conference on Malignant Lymphoma2008 June 4–7
   Google Scholar
• RobinsonKSWilliamsMEvan der JagtRHPhase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin’s lymphomaJ Clin Oncol200826274473447918626004
   PubMed Web of Science ®Google Scholar
• KoenigsmannMKnaufWHeroldMFludarabine and bendamustine in refractory and relapsed indolent lymphoma – a multicenter phase I/II trial of the East German society of hematology and oncology (OSHO)Leuk Lymphoma2004451821182715223642
   PubMed Web of Science ®Google Scholar
• GhandiVMetabolism and mechanisms of action of bendamustine: Rationales for combination therapiesSemin Oncol200229Suppl 13411
   Google Scholar
• SchwãnenCHeckerTHũbingerGIn vitro evaluation of bendamustine induced apoptosis in B-chronic lymphocytic leukemiaLeukemia2002162096210512357363
   PubMed Web of Science ®Google Scholar
• ChowKUBoehrerSGeduldigKIn vitro induction of apoptosis of neoplastic cells in low-grade non-Hodgkin’s lymphomas using combinations of established cytotoxic drugs with bendamustineHaematologica20018648549311410411
   PubMed Web of Science ®Google Scholar
• WeideRHeymannsJGoresAKopplerHBendamustine, mitoxantrone and rituximab (BMR): A new effective regimen for refractory or relapsed indolent lymphomasLeuk Lymphoma20024332733111999564
   PubMed Web of Science ®Google Scholar
• WeideRPandorfAHeymannsJBendamustine/mitoxantrone/rituximab (BMR): A very effective, well tolerated outpatient chemoimmunotherapy for relapsed and refractory CD20-positive indolent malignancies. Final results of a pilot studyLeuk Lymphoma2004452445244915621757
   PubMed Web of Science ®Google Scholar
• WeideRHessGKoepplerHHigh anti-lymphoma activity of bendamustine/mitoxantrone/rituximab (BMR) in rituximab pretreated relapsed or refractory indolent lymphomas. A multicenter phase II study of the German low grade lymphoma study group (GLSG)Leuk Lymphoma2007481299130617613757
   PubMed Web of Science ®Google Scholar
• MoosmannPRHeizmannMKotrubczikNWeekly treatment with a combination of bendamustine and bortezomib in relapsed or refractory indolent NHL: A single-center phase I/II studySan Francisco, CAProceedings from the 50th Annual American Society of Hematology Meeting2008 Dec 6–9;Blood 1574
   Google Scholar
• de VosSDakhilSMcLaughlinPPhase 2 study of bortezomib weekly or twice weekly plus rituximab in patients with follicular lymphoma (FL) or marginal zone (MZL) lymphoma: Final resultsOrlando, FLProceedings from the 48th Annual American Society of Hematology Meeting2006 Dec 8–12Blood 2006: 694
   Google Scholar
• MatousJLetzerJRosenPBortezomib, bendamustine, and rituximab in patients with relapsed or refractory follicular lymphoma: Dose finding results of the VERTICAL trialOrlando, FLProceedings from the 45th Annual Meeting of the American Society of Clinical Oncology2009 May 29–June 2J Clin Oncol. 8550
   Google Scholar
• HeroldMSchulzeANeiderweiserDBendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin’s lymphoma and mantle cell lymphoma: Results of a randomized phase III trial (OSHO # 19)J Cancer Res Clin Oncol200613210511216088404
   PubMed Web of Science ®Google Scholar
• RummelMJvon GruenhagonUNiederleNBendamustine plus rituximab versus CHOP-R in the first-line treatment of patients with indolent and mantle cell lymphomas-first interim results of a randomized phase III study of the StiL (Study Group Indolent Lymphomas, Germany)Atlanta, GAProceedings from the 49th Annual American Society of Hematology Meeting2007 Dec 8–11Blood 385
   Google Scholar
• RummelMJvon GruenhagonUNiederleNBendamustine plus rituximab versus CHOP plus rituximab in the first-line treatment of patients with follicular, indolent, and mantle cell lymphomas: Second interim analysis of a randomized phase III study of the Study Group Indolent Lymphomas (StiL)San Francisco, CAProceedings from the 50th Annual American Society of Hematology2008 Dec 6–8Blood 2596
   Google Scholar
• WeidmannEFauthFAtmacaAFirst-line treatment with rituximab and bendamustine in old patients (80 years and older) with aggressive B-cell lymphomas – an interim analysis of an ongoing phase II studyBerlin, GermanyProceedings from the 14th Congress of the European Hematology Association2009 June 4–7
   Google Scholar